Skip to main content
SpringerLink
Log in

Cost implications of increased use of direct oral anticoagulants in AF

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Rodwin BA, et al. Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications. American Journal of Medicine : 2 Oct 2018. Available from: URL: http://doi.org/10.1016/j.amjmed.2018.09.026

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost implications of increased use of direct oral anticoagulants in AF. PharmacoEcon Outcomes News 814, 2 (2018). https://doi.org/10.1007/s40274-018-5345-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5345-9

Search

Navigation